Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors

Next Previous
X
Search
Trial Profile

Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Cardiovascular disorders; Obesity
  • Focus Therapeutic Use
  • Acronyms CRESCENDO
  • Sponsors Sanofi; Sanofi-Synthelabo

    • Most Recent Events

    • 19 Jan 2022 This trial has been completed in Greece (End Date: 29 Apr 2009), according to European Clinical Trials Database record.
    • 19 Oct 2012 Planned number of patients changed from 18695 to 20300.
    • 14 Aug 2010 The CRESCENDO study was discontinued early due to concerns by health regulatory authorities about suicide in patients receiving rimonabant.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top